Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Compensatory mutations rescue the virus replicative capacity of VIRIP-resistant HIV-1.

Antiviral research - 1 Dec 2011

González-Ortega Emmanuel, Ballana Ester, Badia Roger, Clotet Bonaventura, Esté José A

Abstract excerpt

VIRIP has been identified as a highly specific natural inhibitor of HIV-1 that blocks HIV-1 gp41-dependent fusion by interacting with the gp41 fusion peptide. Two analogues of VIRIP (VIR-353 and VIR-576) with a few amino acid changes increase its antiretroviral potency by two orders of magnitude in cell culture. VIR-576 has been shown effective in a phase I/II clinical trial. Resistance to VIRIP and its analogue...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to alpha 1-Antitrypsin
Share to Drug Resistance, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Synergism

Share to Enfuvirtide

Share to HIV Envelope Protein gp41

Share to HIV Fusion Inhibitors

Share to Human Immunodeficiency Virus Proteins

Share to Peptide Fragments

Source

Identifiers

PMID: 22027647
DOI: 10.1016/j.antiviral.2011.10.010

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Compensatory mutations rescue the virus replicative capacity of VIRIP-resistant HIV-1.PMID 22027647Read ↗

Reduced Susceptibility to VIRIP-Based HIV-1 Entry Inhibitors Has a High Genetic Barrier and Severe Fitness Costs.Semantic proximity Read ↗

Human immunodeficiency virus type 1 variants resistant to first- and second-version fusion inhibitors and cytopathic in ex vivo human lymphoid tissue.Semantic proximity Read ↗

Exploiting Genetic Interference for Antiviral Therapy.Semantic proximity Read ↗

HIV-1 mutates to evade IFITM1 restriction.Semantic proximity Read ↗

Resistance of human immunodeficiency virus type 1 to a third-generation fusion inhibitor requires multiple mutations in gp41 and is accompanied by a dramatic loss of gp41 function.Semantic proximity Read ↗

Reverted HIV-1 Mutants in CD4+ T-Cells Reveal Critical Residues in the Polar Region of Viral Envelope Glycoprotein.Semantic proximity Read ↗

HIV-1 adaptation studies reveal a novel Env-mediated homeostasis mechanism for evading lethal hypermutation by APOBEC3G.Semantic proximity Read ↗

Discovery and Engineering of a Therapeutic Interfering Particle (TIP): a combination self-renewing antiviralSemantic proximity Read ↗

The V3 Loop of HIV-1 Env Determines Viral Susceptibility to IFITM3 Impairment of Viral InfectivitySemantic proximity Read ↗

Altered Env conformational dynamics as a mechanism of resistance to peptide-triazole HIV-1 inactivators.Semantic proximity Read ↗

Mutations conferring resistance to human immunodeficiency virus type 1 fusion inhibitors are restricted by gp41 and Rev-responsive element functions.Semantic proximity Read ↗

Characterization of resistance to a potent D-peptide HIV entry inhibitor.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.